Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Clinical trial NCT04526509 · TERMINATED
Trial details
- NCT number
- NCT04526509
- Sponsor
- Adaptimmune
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-21
- Primary completion
- 2023-06-08
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.